← Leaderboards
Hayley Sarah McLoughlin
University Of Michigan At Ann Arbor
$3,898,382
Attributed
$5,167,576
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $964.3K · FY2018–25$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,167,576 · 4
By mechanism
R01$2,629,188 · 2
U01$2,103,449 · 1
R21$434,939 · 1
Top collaborators
- Henry L Paulson4 shared
- Gulin Oz1 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Eva L Feldman$26,770,746
- Frank C Brosius$16,808,691
- Matthias Kretzler$40,447,062
- Subramaniam Pennathur$11,719,201
- Amy E. Rumora$985,566
Others in their field
Other Emerging Leaders on “Mouse Model”
- James Dale Berry · Brigham And Women'S Hospital$25,017,559
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$13,186,126
- Nuno Macarico Da Costa · Allen Institute$11,726,937
- Forrest Christie Collman · Allen Institute$11,726,937
- Jacqueline K White · Jackson Laboratory$11,670,339
- Thomas Dick · Rbhs-New Jersey Medical School$11,611,284
Research focus
Mouse ModelGenesMachado-Joseph DiseaseCag RepeatAntisense OligonucleotidesMutantBehavioralKnock-DownPathogenesisHuman DiseaseTissuesPolyglutamineBrain RegionProteinsHuntington DiseaseBiological MarkersTherapeutic TargetLeadTargeted TreatmentPathogenicityCellsMortalityNeurogliaImpairment
Grant awards (11)
Investigating Peripheral Neuropathy in Spinocerebellar Ataxia Type 3$460,643
R01 · FY2025 · NS · contact PI
Nonneuronal Mechanisms of Polyglutamine Neurodegeneration$418,332
R01 · FY2025 · NS · contact PI
Nonneuronal Mechanisms of Polyglutamine Neurodegeneration$405,783
R01 · FY2024 · NS · contact PI
Nonneuronal Mechanisms of Polyglutamine Neurodegeneration$418,332
R01 · FY2023 · NS · contact PI
Nonneuronal Mechanisms of Polyglutamine Neurodegeneration$448,120
R01 · FY2022 · NS · contact PI
Preclinical Development of Antisense Oligonucleotide Therapy for Spinocerebellar Ataxia Type 3$486,330
U01 · FY2021 · NS · contact PI
Nonneuronal Mechanisms of Polyglutamine Neurodegeneration$477,978
R01 · FY2021 · NS · contact PI
Preclinical Development of Antisense Oligonucleotide Therapy for Spinocerebellar Ataxia Type 3$552,105
U01 · FY2020 · NS · contact PI
Preclinical Development of Antisense Oligonucleotide Therapy for Spinocerebellar Ataxia Type 3$528,534
U01 · FY2019 · NS · contact PI
Defining Biomarkers for Spinocerebellar Ataxia Type 3$434,939
R21 · FY2019 · NS · contact PI
Preclinical Development of Antisense Oligonucleotide Therapy for Spinocerebellar Ataxia Type 3$536,480
U01 · FY2018 · NS · contact PI